Gun M. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 09, 2026

Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management.

Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management.

Journal: International journal of radiation oncology, biology, physics
Published: October 04, 2025

Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast Cancer.

Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast Cancer.

Journal: Clinical breast cancer
Published: August 23, 2025

Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer.

Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer.

Journal: Genome biology
Published: August 08, 2025

Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast Cancer.

Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast Cancer.

Journal: Journal of breast cancer
Published: July 23, 2025

Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15).

Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15).

Journal: Breast (Edinburgh, Scotland)
Published: January 06, 2025

GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours.

GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours.

Journal: British journal of cancer
Published: October 18, 2024

Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.

Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.

Journal: The Lancet. Oncology
Published: September 10, 2024

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).

Journal: BMC cancer
Published: September 06, 2024

Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.

Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.

Journal: Nature medicine
Published: June 24, 2024

Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer.

Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer.

Journal: Journal of cachexia, sarcopenia and muscle
Published: May 24, 2024
Showing 1-12 of 71

Last Updated: 09/26/2026